CD59 and cancer: It would also align with studies demonstrating strong increase of CD95 expression in primary PCa cells after docetaxel treatment [34], positive correlation of higher levels of soluble CD95, docetaxel resistance and shorter cancer-specific survival in PCa patients [67], as well as incline in CD59 expression in treatment naïve PCa correlating with early biochemical relapse and worse prognosis [68].